Malcolm Ranson

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Darren A.E. Cross, Susan Ashton, Serban Ghiorghiu et al. · Cancer Discovery · 2014 · 2.2K citations · Full text

Medicine, Oncology, Pharmacology +13

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

Pasi A. Jänne, James Chih‐Hsin Yang, Dong‐Wan Kim et al. · New England Journal of Medicine · 2015 · 2.1K citations · Full text

Medicine, Oncology, Pharmacology +16

Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non–Small-Cell Lung Cancer

Matthew Krebs, Robert Szczepaniak‐Sloane, Lynsey Priest et al. · Journal of Clinical Oncology · 2011 · 865 citations · Full text

Medicine, Clinical Sciences, Oncology +17

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types

José Baselga, Danny Rischin, Malcolm Ranson et al. · Journal of Clinical Oncology · 2002 · 831 citations

Medicine, Oncology, Pharmacology +16

ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial

Malcolm Ranson, Lisa A. Hammond, D. K. Ferry et al. · Journal of Clinical Oncology · 2002 · 763 citations

Medicine, Oncology, Pharmacology +14